OncoMatch/Clinical Trials/NCT06416007
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
Is NCT06416007 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for cancer.
The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy
Cannot have received: radiosensitizing agents
Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Cincinnati Medical Center · Cincinnati, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify